News
Santhera logo

Santhera licenses LHON drug to Chiesi for €93m

Santhera has announced it is licensing its LHON drug Raxone (idebenone) to Chiesi Group for an upfront payment of €44 million and milestone payments of up to €49 million, as it looks to foc

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

R&D

Partner Content

Partner Content
LEAP HR: Life Sciences Europe
Partner Content

LEAP HR: Life Sciences Europe

Europe’s Only Industry-Specific Meeting Advancing HR Excellence in Life Sciences